The safety of intrauterine contraception initiation among women with current asymptomatic cervical infections or at increased risk of sexually transmitted infections

Contraception

Volumn 94, Issue 6, 2016, Pages 701-712

  Jatlaoui, Tara C ^a   Simmons, Katharine B ^a   Curtis, Kathryn M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cervical infection; Chlamydia; Gonorrhea; Intrauterine device; Pelvic inflammatory disease

Indexed keywords

ALGORITHM; CHLAMYDIASIS; COPPER INTRAUTERINE DEVICE; DEVICE SAFETY; GONORRHEA; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; PELVIC INFLAMMATORY DISEASE; REVIEW; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; SEXUALLY TRANSMITTED DISEASE; SYSTEMATIC REVIEW; CONTRACEPTION; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; PROCEDURES; SEXUALLY TRANSMITTED DISEASES;

CONTRACEPTION; EQUIPMENT SAFETY; FEMALE; HUMANS; INTRAUTERINE DEVICES; PELVIC INFLAMMATORY DISEASE; RISK ASSESSMENT; SEXUALLY TRANSMITTED DISEASES;

EID: 84995948308     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2016.05.013     Document Type: Review

References (31)

1. [1] Trussell, J, Contraceptive failure in the United States. Contraception 83 (2011), 397–404.
2. [2] U S. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep, 59, 2010, 1–86.
3. [3] Institute G., Contraceptive use in the United States. Fact Sheet, 2015.
4. [4] Romero, L, Pazol, K, Warner, L, Gavin, L, Moskosky, S, Besera, G, et al. Vital signs: trends in use of long-acting reversible contraception among teens aged 15–19 years seeking contraceptive services—United States, 2005–2013. MMWR Morb Mortal Wkly Rep 64 (2015), 363–369.
5. [5] Tyler, CP, Whiteman, MK, Zapata, LB, Curtis, KM, Hillis, SD, Marchbanks, PA, Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol 119 (2012), 762–771.
6. [6] Grimes, DA, Intrauterine device and upper-genital-tract infection. Lancet 356 (2000), 1013–1019.
7. [7] Farley, TM, Rosenberg, MJ, Rowe, PJ, Chen, JH, Meirik, O, Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 339 (1992), 785–788.
8. [8] U.S. selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep 62 (2013), 1–60.
9. [9] Brunham, RC, Gottlieb, SL, Paavonen, J, Pelvic inflammatory disease. N Engl J Med 372 (2015), 2039–2048.
10. [10] Workowski, KA, Bolan, GA, Centers for Disease Control, Prevention, Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64 (2015), 1–137.
11. [11] Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, P, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
12. [12] Harris, RP, Helfand, M, Woolf, SH, Lohr, KN, Mulrow, CD, Teutsch, SM, et al. Current methods of the US preventive services task force: a review of the process. Am J Prev Med 20 (2001), 21–35.
13. [13] Birgisson, NE, Zhao, Q, Secura, GM, Madden, T, Peipert, JF, Positive testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health (Larchmt) 24 (2015), 354–359.
14. [14] Cropsey, KL, Matthews, C, Campbel, S, Ivey, S, Adawadkar, S, Long-term, reversible contraception use among high-risk women treated in a university-based gynecology clinic: comparison between IUD and Depo-Provera. J Womens Health (Larchmt) 19 (2010), 349–353.
15. [15] Campbell, SJ, Cropsey, KL, Matthews, CA, Intrauterine device use in a high-risk population: experience from an urban university clinic. Am J Obstet Gynecol, 197, 2007, 193 [e1–6; discussion e6–7].
16. [16] Grentzer, JM, Peipert, JF, Zhao, Q, McNicholas, C, Secura, GM, Madden, T, Risk-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae prior to intrauterine device insertion. Contraception 92 (2015), 313–318.
17. [17] Murphy, PA, Jacobson, J, Turok, DK, Criterion-based screening for sexually transmitted infection: sensitivity, specificity, and predictive values of commonly used questions. J Midwifery Womens Health 57 (2012), 622–628.
18. [18] Morrison, CS, Murphy, L, Kwok, C, Weiner, DH, Identifying appropriate IUD candidates in areas with high prevalence of sexually transmitted infections. Contraception 75 (2007), 185–192.
19. [19] Morrison, CS, Sekadde-Kigondu, C, Miller, WC, Weiner, DH, Sinei, SK, Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device candidates. Contraception 59 (1999), 97–106.
20. [20] Faundes, A, Telles, E, Cristofoletti, ML, Faundes, D, Castro, S, Hardy, E, The risk of inadvertent intrauterine device insertion in women carriers of endocervical chlamydia trachomatis. Contraception 58 (1998), 105–109.
21. [21] Sufrin, CB, Postlethwaite, D, Armstrong, MA, Merchant, M, Wendt, JM, Steinauer, JE, Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol 120 (2012), 1314–1321.
22. [22] Papic, M, Wang, N, Parisi, SM, Baldauf, E, Updike, G, Schwarz, EB, Same-day intrauterine device placement is rarely complicated by pelvic infection. Womens Health Issues 25 (2015), 22–27.
23. [23] Workowski, KA, Berman, S, Centers for Disease C, Prevention, Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 59 (2010), 1–110.
24. [24] Toivonen, J, Luukkainen, T, Allonen, H, Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 77 (1991), 261–264.
25. [25] Centers for Disease Control, Prevention, Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014. MMWR Recomm Rep 63 (2014), 1–19.
26. [26] Mohllajee, AP, Curtis, KM, Peterson, HB, Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 73 (2006), 145–153.
27. [27] Winner, B, Peipert, JF, Zhao, Q, Buckel, C, Madden, T, Allsworth, JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 366 (2012), 1998–2007.
28. [28] McNicholas, C, Peipert, JF, Maddipati, R, Madden, T, Allsworth, JE, Secura, GM, Sexually transmitted infection prevalence in a population seeking no-cost contraception. Sex Transm Dis 40 (2013), 546–551.
29. [29] Schwarz, EB, Papic, M, Parisi, SM, Baldauf, E, Rapkin, R, Updike, G, Routine counseling about intrauterine contraception for women seeking emergency contraception. Contraception 90 (2014), 66–71.
30. [30] Turok, DK, Godfrey, EM, Wojdyla, D, Dermish, A, Torres, L, Wu, SC, Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod 28 (2013), 2672–2676.
31. [31] Turok, DK, Gurtcheff, SE, Handley, E, Simonsen, SE, Sok, C, Murphy, P, A pilot study of the copper T380a IUD and oral levonorgestrel for emergency contraception. Contraception 82 (2010), 520–525.